Association of CYP1B1 gene polymorphisms with susceptibility to endometrial cancer: a meta-analysis.
The objective of this meta-analysis was to quantitatively summarize the association of CYP1B1 gene polymorphisms and endometrial cancer risk. Data were collected from the following electronic databases: PubMed,Elsevier Science Direct, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure and Wanfang, with the last report up to June 2010. Meta-analysis was conducted in a fixed/random effect model. Out of the 715 papers retrieved 12 studies (3605 cases and 5692 controls) on the association of CYP1B1 gene polymorphisms with endometrial cancer risk in different ethnic groups were identified. Meta-analysis was performed for CYP1B1 gene polymorphisms: R48G (C/G, five studies), L432V (C/G, 12 studies), N453S (A/G, four studies), and A119S (G/T, five studies). We did not detect any association of CYP1B1 gene A119S polymorphism with endometrial cancer. An association of CYP1B1 gene R48G polymorphism with endometrial cancer was found [GG vs. GC+CC: odds ratio (OR)=0.55, 95% confidence interval (CI): 0.42-0.73, P<0.0001; GG vs. CC: OR=0.46, 95% CI: 0.23-0.91, P=0.03]. We found that CYP1B1 gene L432V polymorphism was associated with a significantly increased risk of endometrial cancer (G vs. C: OR=1.23, 95% CI: 1.06-1.43, P=0.007; GC+GG vs. CC:OR=1.24, 95% CI: 1.08-1.43, P=0.003; GC vs. CC: OR=1.16, 95% CI: 1.04-1.29, P=0.009). Moreover, we detected the association of CYP1B1 gene N453S polymorphism with endometrial cancer (G vs. A: OR=0.82,95% CI: 0.72-0.94, P=0.005; GA vs. AA: OR=0.81, 95% CI: 0.69-0.95, P=0.01). In conclusion, this meta-analysis provides strong evidence that CYP1B1 gene R48G, L432V, and N453S polymorphisms are associated with endometrial cancer risk, but not A119S.